Navigation Links
Onyx Pharmaceuticals Announces December 2009 Investor Events
Date:11/25/2009

EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December:

ASH Briefing

December 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET

Principal investigators will discuss data presentations surrounding carfilzomib in relapsed and/or refractory multiple myeloma, as featured at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA. The teleconference will begin at 9:00 a.m. CT/10:00 a.m. ET on December 7, 2009. The live webcast will be available at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

or by dialing 847-413-3362 and using the passcode 25914947. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 25914947 later in the day. The replay will be available on the Onyx website through January 7, 2010.

Analyst Briefing on Development Program

December 17, 2009 - 8:30 a.m. ET

Onyx management will host an overview of its development program on December 17, 2009 at 8:30 a.m. ET. The program will feature presentations on multiple tumor types by external clinical investigators and members of management. Subsequent to the prepared remarks, the company will conduct a Q&A session with panelists and members of the management team. Further details regarding Analyst Day, including webcast information, will be announced closer to the event.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®( )(sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801 is a targeted alpha-folate inhibitor currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have soared 82% ... Trends Report). As travelers visit both urban destinations, they are faced with exploration ... exposure. In response, the outdoor industry has blurred the lines between fashion and ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... medical society dedicated to advancing the science and clinical practice of radiosurgery, ... RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in ... Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most ... kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with ...
(Date:3/28/2017)... ... , ... WHO: , Dr. Paul Thomas; Dr. Brian Hooker; Dr. Judy Mikovits; ... scientists will speak to the press on behalf of over 200 doctors, scientists, and ... safety commission. , WHERE: , Zenger Room, National Press Club, 529 14th Street ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business ... has begun to serve as its new executive director. Mr. Still was selected through ... Committee. , “Bob, as he is known to our members, has been a ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  NuVasive, Inc. ... on transforming spine surgery with minimally disruptive, procedurally-integrated ... (FDA) 510(k) clearance of the CoRoent® Small Interbody™ ... contiguous levels in the cervical spine. This marks ... to be used at up to four contiguous ...
(Date:3/29/2017)... 2017   Dynatronics Corporation (NASDAQ: ... Cynthia L. McHenry (Cyndi) as Vice ... leading Dynatronics manufacturing, distribution, and purchasing operations across ... CEO Kelvyn H. Cullimore, Jr. ... process conducted by the company as it continues ...
(Date:3/29/2017)... , March 29, 2017 NetworkNewsWire ... ... the public safety in regulating marijuana, but economic arguments also ... creation, and reduced law enforcement costs. However, to legalize and ... provided by SinglePoint, Inc. (OTC: SING) ( SING Profile ), ...
Breaking Medicine Technology: